Literature DB >> 27486793

LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.

B Schellhaas1, D Wildner1, L Pfeifer1, R S Goertz1, A Hagel1, M F Neurath1, D Strobel1.   

Abstract

Purpose: To develop a contrast-enhanced ultrasound algorithm (LI-RADS-CEUS = liver imaging reporting and data system with contrast-enhanced ultrasound) for the diagnosis of hepatocellular carcinoma (HCC) in patients at risk. Materials and
Methods: A CEUS algorithm (LI-RADS-CEUS) was designed analogously to CT- and MRI-based LI-RADS. LI-RADS-CEUS was evaluated retrospectively in 50 patients at risk with confirmed HCC or non-HCC lesions (test group) with subsequent validation in a prospective cohort of 50 patients (validation group). Results were compared to histology, CE-CT and CE-MRI as reference standards.
Results: Tumor diagnosis in the test group/validation group (n = 50/50) were 46/41 HCCs, 3/3 intrahepatic cholangiocellular carcinomas (ICCs) and 1/6 benign lesions. The diagnostic accuracy of LI-RADS-CEUS for HCC, ICC and non-HCC-non-ICC-lesions was 89 %. For the diagnosis of HCC, the diagnostic accuracy was 93.5 % (43/46 cases) in the test group and 95.1 % (39/41 cases) in the validation group. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 94.3 %, 66.6 %, 94.3 % and 66.6 %, respectively (mean values from both cohorts). Histological findings of HCC were available in 40 versus 23 cases (in total: G1 / G2/G3: 15/35/13). Arterial hyperenhancement was seen in 68/87 (78.2 %) of HCCs. Arterial hyperenhancement with subsequent portal venous or late phase hypoenhancement was seen in 66 % of HCCs.
Conclusion: LI-RADS-CEUS offers a CEUS algorithm for standardized assessment and reporting of focal liver lesions in patients at risk for HCC. Arterial hyperenhancement in CEUS is the key feature for the diagnosis of HCC in patients at risk, whereas washout is not a necessary prerequisite. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27486793     DOI: 10.1055/s-0042-112221

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  9 in total

1.  Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.

Authors:  Barbara Schellhaas; Matthias Hammon; Deike Strobel; Lukas Pfeifer; Christian Kielisch; Ruediger S Goertz; Alexander Cavallaro; Rolf Janka; Markus F Neurath; Michael Uder; Hannes Seuss
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

Review 2.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.

Authors:  Jia-Min Pan; Wei Chen; Yan-Ling Zheng; Mei-Qing Cheng; Dan Zeng; Hui Huang; Yang Huang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Hang-Tong Hu; Li-Da Chen; Wei Wang
Journal:  Br J Radiol       Date:  2021-10-01       Impact factor: 3.629

4.  Effect of contrast-enhanced ultrasound on differential diagnosis of intrahepatic cholangiocarcinoma and arterial phase enhanced hepatic inflammatory lesions.

Authors:  Shanshan Yin; Qiuli Cui; Kun Yan; Wei Yang; Wei Wu; Liping Bao; Minhua Chen
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

5.  Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.

Authors:  Mishal Mendiratta-Lala; Everett Gu; Dawn Owen; Kyle C Cuneo; Latifa Bazzi; Theodore S Lawrence; Hero K Hussain; Matthew S Davenport
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-24       Impact factor: 7.038

6.  Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016.

Authors:  Juanjuan Zhang; Yanyan Yu; Ying Li; Lunshou Wei
Journal:  Oncotarget       Date:  2017-08-07

7.  The preliminary application of liver imaging reporting and data system (LI-RADS) with contrast-enhanced ultrasound (CEUS) on small hepatic nodules (≤ 2cm).

Authors:  Wenwu Ling; Manni Wang; Xuelei Ma; Tingting Qiu; Jiawu Li; Qiang Lu; Yan Luo
Journal:  J Cancer       Date:  2018-07-30       Impact factor: 4.207

8.  Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature.

Authors:  Yuki Yamashita; Satoru Joshita; Hiroyuki Kobayashi; Shun-Ichi Wakabayashi; Ayumi Sugiura; Tomoo Yamazaki; Takeji Umemura
Journal:  Medicina (Kaunas)       Date:  2021-03-18       Impact factor: 2.430

9.  Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.

Authors:  D Strobel; E-M Jung; M Ziesch; M Praktiknjo; A Link; C F Dietrich; C Klinger; M Schultheiß; D Jesper; B Schellhaas
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.